YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$12.27 USD
+0.13 (1.07%)
Updated May 29, 2024 04:00 PM ET
After-Market: $12.29 +0.02 (0.16%) 5:06 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Y-mAbs Therapeutics, Inc. (YMAB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$21.33 | $26.00 | $12.00 | 75.70% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Y-mAbs Therapeutics, Inc. comes to $21.33. The forecasts range from a low of $12.00 to a high of $26.00. The average price target represents an increase of 75.7% from the last closing price of $12.14.
Analyst Price Targets (6 )
Broker Rating
Y-mAbs Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.78 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.78 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, four are Strong Buy, representing 66.67% of all recommendations. A month ago, Strong Buy represented 66.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 2 | 2 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.78 | 1.78 | 1.78 | 1.96 | 1.96 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/6/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
3/4/2024 | BMO Capital Markets | Etzer Darout | Strong Buy | Strong Buy |
3/4/2024 | Canaccord Genuity | William J Plovanic | Strong Buy | Strong Buy |
2/12/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.78 |
ABR (Last week) | 1.78 |
# of Recs in ABR | 6 |
Average Target Price | $21.33 |
LT Growth Rate | 31.40% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 91 of 252 |
Current Quarter EPS Est: | -0.10 |